FULGENT GENETICS, INC. Cash, Period Increase (Decrease)
FULGENT GENETICS, INC. (FLGT) reported Cash, Period Increase (Decrease) of -$1.22 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-14.
Discontinued › Notes
us-gaap:CashPeriodIncreaseDecrease · last filed 2018-05-14
- FULGENT GENETICS, INC. cash, period increase (decrease) for the quarter ending 2018-03-31 was -$1.22M.
- FULGENT GENETICS, INC. cash, period increase (decrease) for the quarter ending 2017-12-31 was -$2.99M.
- FULGENT GENETICS, INC. cash, period increase (decrease) for the quarter ending 2017-09-30 was -$2.00M.
- FULGENT GENETICS, INC. cash, period increase (decrease) for the quarter ending 2017-06-30 was $4.74M, a 68.12% decline year-over-year.
- FULGENT GENETICS, INC. cash, period increase (decrease) for fiscal 2017 was -$1.41M, a 119.02% decline from fiscal 2016.
- FULGENT GENETICS, INC. cash, period increase (decrease) for fiscal 2016 was $7.40M, a 2169.63% increase from fiscal 2015.
- FULGENT GENETICS, INC. cash, period increase (decrease) for fiscal 2015 was $326.00K.
- FULGENT GENETICS, INC. cash, period increase (decrease) for fiscal 2014 was -$1.18M.
| Period end | Cash, Period Increase (Decrease) 3 month | Cash, Period Increase (Decrease) 6 month | Cash, Period Increase (Decrease) 9 month | Cash, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$1.22M 10-Q · filed 2018-05-14 | -$4.20M derived: sum of 2 quarters · filed 2018-05-14 | -$6.20M derived: sum of 3 quarters · filed 2018-05-14 | -$1.46M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-12-31 | -$2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$4.98M derived: sum of 2 quarters · filed 2018-03-20 | -$244.00K derived: sum of 3 quarters · filed 2018-03-20 | -$1.41M 10-K · filed 2018-03-20 |
| 2017-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $2.74M derived: sum of 2 quarters · filed 2017-11-13 | $1.58M 10-Q · filed 2017-11-13 | $1.27M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $3.58M 10-Q · filed 2017-08-14 | $3.27M derived: sum of 3 quarters · filed 2018-05-14 | -$4.59M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-03-31 | -$1.16M 10-Q · filed 2018-05-14 | -$1.47M derived: sum of 2 quarters · filed 2018-05-14 | -$9.33M derived: sum of 3 quarters · filed 2018-05-14 | $5.54M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | -$308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$8.16M derived: sum of 2 quarters · filed 2018-03-20 | $6.70M derived: sum of 3 quarters · filed 2018-03-20 | $7.40M 10-K · filed 2018-03-20 |
| 2016-09-30 | -$7.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $7.01M derived: sum of 2 quarters · filed 2017-11-13 | $7.71M 10-Q · filed 2017-11-13 | $6.90M derived: sum of 4 quarters · filed 2017-11-13 |
| 2016-06-30 | $14.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $15.56M 10-Q · filed 2017-08-14 | $14.75M derived: sum of 3 quarters · filed 2017-08-14 | |
| 2016-03-31 | $698.00K 10-Q · filed 2017-05-09 | -$112.00K derived: sum of 2 quarters · filed 2017-05-09 | ||
| 2015-12-31 | -$810.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | $326.00K 10-K · filed 2017-03-17 | ||
| 2015-09-30 | $1.14M 10-Q · filed 2016-11-14 | |||
| 2014-12-31 | -$1.18M 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |